Established in late 1999

1

• Established in late 1999
• Scientific/clinical resources
• Ethics committees
• Regulatory body

TT - 2002
2

• SAAVI aims to develop an affordable, effective
  and locally relevant preventative HIV vaccine for
  southern Africa

3
HIV genetic diversity
C. Williamson et al
4
Making the vaccine
Testing the vaccine
Others
Advocacy community
Ethical issues
TT - 2002
5
What do we expect from an HIV vaccine?
6
Viral load in HIV
Amount of HIV
7
Potential end-points of HIV-vaccine efficacy
trials
8
SAAVI Challenges
TT - 2002
9
Making the vaccine
Testing the vaccine
Others
Advocacy community
Ethical issues
TT - 2002
10
Supporters and Funds
TT - 2002
11

• Good vaccine candidates
• HIV subtypes
• Community involvement
• Ethical studies
• Access to product
• Pricing
• Technology transfer

Appropriate Clinical Trials
30 million
TT - 2002
12

• Product?
• When?
• What dose?
• Manufacturing plant
• Personnel
• Dose price
• Distribution capacity

Manufacturing

• Clinical trials lot
• Bulk supply

350 million
TT - 2002
13

• Government
• Medicines Control Council
• Ethics committees
• Medical aids
• Life Insurance
• Blood transfusion services
• State Vaccine Institute

Strategic national alliances
TT - 2002
14
Strategic international alliances

• NIH
• HVTN
• IAVI
• AAVP
• EU
• Public / private

TT - 2002
15
CONCLUSIONS

• SAAVI has dynamic team
• Different to all other initiatives
• Committed to excellence
• Massive / maturing challenges
• Consolidate and expand

TT - 2002